The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receiving multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosafamide (AI): Randomized cross-over study.
Saroj Vadhan-Raj
Research Funding - Merck
Xiao Zhou
No relevant relationships to disclose
Dejka M. Araujo
No relevant relationships to disclose
Neeta Somaiah
No relevant relationships to disclose
Anthony Paul Conley
No relevant relationships to disclose
Vinod Ravi
No relevant relationships to disclose
Mary Daniel
No relevant relationships to disclose
Robert S. Benjamin
Stock Ownership - Merck (I)
Shreyaskumar Patel
Consultant or Advisory Role - GlaxoSmithKline; Johnson & Johnson; Novartis
Research Funding - Astex Therapeutics; Eisai; Infinity Pharmaceuticals; Johnson & Johnson; Morphotek; PharmaMar